4D Molecular Therapeutics (FDMT) Price & Analysis

Compare

416 Followers

FDMT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.24 - $17.41

Previous CloseN/A

Volume165.32K

Average Volume (3M)1.83M

Market Cap

$304.97M

Enterprise Value-$62.66M

Total Cash (Recent Filing)$293.23M

Total Debt (Recent Filing)$23.08M

Price to Earnings (P/E)―

Beta1.17

Next Earnings

Nov 05, 2025

EPS Estimate

-1.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.98

Shares Outstanding46,702,470

10 Day Avg. Volume922,251

30 Day Avg. Volume1,829,739

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.21

Enterprise Value/Revenue-1.90K

Enterprise Value/Gross Profit17.22

Enterprise Value/Ebitda0.28

Forecast

1Y Price Target

$29.38

Price Target Upside349.92% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical Trials ProgressPh1 enrollment completion of 4D-710 in cystic fibrosis lower dose cohorts shows progress in clinical trials.

Gene Therapy AdvancementsUpdated Phase 2a SPECTRA trial data supports gene therapy 4D-150 durability in diabetic macular edema patients, which could be paradigm-shifting in the treatment of retinal vascular diseases.

Research And DevelopmentFDMT added two additional endpoints to assess 4D-710’s clinical profile in more detail, indicating a thorough approach to research.

Bears Say

Commercial UncertaintyThere is still a level of uncertainty around commercial dynamics for a gene therapy.

Price Target AdjustmentPrice target reduced to $16 from $17, reflecting updated R&D expenses for ongoing pivotal trials.

Revenue RisksRisks include failure of developmental candidates to achieve peak commercial revenue estimates due to market size, penetration rates, and/or pricing.

4D Molecular Therapeutics News

4D Molecular price target lowered to $16 from $17 at Leerink

Leerink lowered the firm’s price target on 4D Molecular (FDMT) to $16 from $17 and keeps an Outperform...

17d ago

FDMT

Morning Movers: MeridianLink jumps after pact to be acquired by Centerbridge

Stock futures are largely steady this morning, reflecting a cautious mood ahead of key economic releases and geopolitical...

17d ago

4D Molecular reports 2Q EPS (98c) vs (63c) last year

Reports Q2 revenue $15,000 vs $5,000 last year. “During the past quarter, we advanced our 4D-150 program and...

17d ago

FDMT

4D Molecular presents SPECTRA data at ASRS meeting

4D Molecular (FDMT) announced results from the SPECTRA clinical trial evaluating 4D-150 in patients with diabetic macular edema...

28d ago

FDMT

Buy Rating Affirmed for 4D-150: Promising Phase 2a SPECTRA Trial Results and Market Potential

H.C. Wainwright analyst Matthew Caufield has reiterated their bullish stance on FDMT stock, giving a Buy rating yesterday....

16d ago

FDMT

4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape

4D Molecular Therapeutics, Inc. (FDMT) has disclosed a new risk, in the Sales & Marketing category. 4D Molecular...

16d ago

FDMT

4D Molecular Therapeutics Advances Clinical Programs in Q2 2025

4D Molecular Therapeutics, Inc. ( ($FDMT) ) has released its Q2 earnings. Here is a breakdown of the...

16d ago

FDMT

Promising Phase 2 Trial Results and Strategic Developments Support Buy Rating for 4D Molecular Therapeutics

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on FDMT stock, giving a Buy rating on...

24d ago

FDMT

Promising Potential of 4D-150 in DME and wAMD: Buy Rating Affirmed by Analyst

Bank of America Securities analyst Daniel Giraldo maintained a Buy rating on 4D Molecular Therapeutics today and set...

27d ago

FDMT

Promising Phase 2a SPECTRA Trial Results and Strategic Focus Drive Buy Rating for 4D-150 in Diabetic Macular Edema

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on 4D Molecular Therapeutics today and set a price...

27d ago

FDMT

Bullish Outlook on 4D Molecular Therapeutics’ 4D-150: Promising Clinical Data and Market Potential in Diabetic Macular Edema Treatment

4D Molecular Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Daniel Giraldo...

1M ago

FDMT

4D Molecular Therapeutics’ Phase 3 Trial: A New Hope for Age-Related Macular Degeneration?

4D Molecular Therapeutics, Inc. (($FDMT)) announced an update on their ongoing clinical study. 4D Molecular Therapeutics, Inc. is...

1M ago

FDMT

Optimistic Buy Rating for 4D Molecular Therapeutics Amid Strategic Advancements and Market Interest

4D Molecular Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst on July 2. Analyst...

2M ago

FDMT

Closing Bell Movers: Datadog jumps 11% on S&P 500 inclusion

In the opening hour of the evening session, U.S. equity futures are all little changed, with S&P 500...

2M ago

APP

FDMT FAQ

What was 4D Molecular Therapeutics’s price range in the past 12 months?

4D Molecular Therapeutics lowest stock price was $2.23 and its highest was $17.41 in the past 12 months.

What is 4D Molecular Therapeutics’s market cap?

4D Molecular Therapeutics’s market cap is $304.97M.

When is 4D Molecular Therapeutics’s upcoming earnings report date?

4D Molecular Therapeutics’s upcoming earnings report date is Nov 05, 2025 which is in 69 days.

How were 4D Molecular Therapeutics’s earnings last quarter?

4D Molecular Therapeutics released its earnings results on Aug 11, 2025. The company reported -$0.98 earnings per share for the quarter, missing the consensus estimate of -$0.727 by -$0.253.

Is 4D Molecular Therapeutics overvalued?

According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 4D Molecular Therapeutics pay dividends?

4D Molecular Therapeutics does not currently pay dividends.

What is 4D Molecular Therapeutics’s EPS estimate?

4D Molecular Therapeutics’s EPS estimate is -1.01.

How many shares outstanding does 4D Molecular Therapeutics have?

4D Molecular Therapeutics has 46,702,470 shares outstanding.

What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?

4D Molecular Therapeutics reported an EPS of -$0.98 in its last earnings report, missing expectations of -$0.727. Following the earnings report the stock price went down -1.776%.

Which hedge fund is a major shareholder of 4D Molecular Therapeutics?

Currently, no hedge funds are holding shares in FDMT

4D Molecular Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-38.87%

Trailing 12-Months

Asset Growth

-23.62%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

4D Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

4D Molecular Therapeutics (FDMT) Earnings & Revenues

Historic Earnings Reports

FDMT Stock 12 Month Forecast

Average Price Target

$29.38

▲(349.92% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","46":"$46","12.25":"$12.25","23.5":"$23.5","34.75":"$34.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.38</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,12.25,23.5,34.75,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,9.387692307692308,12.355384615384615,15.323076923076924,18.29076923076923,21.25846153846154,24.22615384615385,27.193846153846152,30.161538461538463,33.129230769230766,36.096923076923076,39.06461538461539,42.0323076923077,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,8.186153846153847,9.952307692307691,11.718461538461538,13.484615384615385,15.250769230769231,17.016923076923078,18.783076923076923,20.549230769230768,22.315384615384616,24.081538461538464,25.847692307692306,27.613846153846154,{"y":29.38,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.42,6.695384615384615,6.970769230769231,7.246153846153846,7.521538461538461,7.796923076923077,8.072307692307692,8.347692307692308,8.623076923076923,8.89846153846154,9.173846153846153,9.44923076923077,9.724615384615385,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.34,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.19,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.01,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.59,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.53,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.99,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.75,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >